Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pharma Aids's Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was BDT104.3 Mil. Therefore, Pharma Aids's EV-to-EBIT ratio for today is 19.08.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Pharma Aids's Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT113.8 Mil. Therefore, Pharma Aids's EV-to-EBITDA ratio for today is 17.48.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Pharma Aids's Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was BDT495.7 Mil. Therefore, Pharma Aids's EV-to-Revenue ratio for today is 4.01.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Pharma Aids's Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT6.2 Mil. Therefore, Pharma Aids's EV-to-FCF ratio for today is 323.03.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Pharma Aids (DHA:PHARMAID) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Pharma Aids's current Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT104.3 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Pharma Aids's current Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT113.8 Mil.
Pharma Aids's current Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT495.7 Mil.
Pharma Aids's current Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT62.9 Mil.
Pharma Aids's current Enterprise Value is BDT1,989.6 Mil.
Pharma Aids's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT6.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids Enterprise Value Related Terms
Pharma Aids Enterprise Value Historical Data
* Premium members only.
The historical data trend for Pharma Aids's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Pharma Aids's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Pharma Aids's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of BDT1,989.6 Mil mean?
Pharma Aids (DHA:PHARMAID) has a Enterprise Value of BDT1,989.6 Mil as of Jul. 17, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Pharma Aids and its competitors.
Is Pharma Aids' Enterprise Value too high?
Pharma Aids' current Enterprise Value is BDT1,989.6 Mil. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Enterprise Value compare to ISRG and BDX?
Pharma Aids' Enterprise Value of BDT1,989.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Pharma Aids and its competitors. Pharma Aids's current Enterprise Value is BDT1,989.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current Enterprise Value is BDT1,989.6 Mil. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Enterprise Value is BDT1,989.6 Mil as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
Enterprise Value: BDT1,989.6 Mil
GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
